A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Completed · Phase 4 · Has a placebo group
Conditions studied: Herpes Genitalis
In brief
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more likely to produce frequent recurrences of GH lesions. Evidence suggests that there are advantages to using suppressive vs. episodic treatment, which include increased intervals between the pain and discomfort of genital herpes recurrences. Therefore, this study will collect safety and efficacy data on suppressive therapy with valaciclovir in subjects newly diagnosed with HSV-2 genital herpes.
Key facts
- Study ID
- NCT00158860
- Run by
- GlaxoSmithKline
- People needed
- 384
- Starts
- 2004-06-21
- Expected to finish
- 2006-07-26
- Last updated by the study team
- 2019-02-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- In overall general good health.
- Females can enter and participate in this study if they are of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or if of childbearing potential, has a negative pregnancy test (urine) at screening and agrees to use GSK stipulated contraceptive methods.
- Must be newly diagnosed with a first recognized episode of GH at the time of the Screening Visit or within 3 months prior to the Screening Visit.
You may not qualify if…
- Known or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV).
- Received an investigational drug in the 30 days prior to the study.
- Receiving systemic antiviral or immunomodulatory treatments.
- Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug.
- Clinically significant impaired renal function as defined by a creatinine clearance <30 ml/min, calculated using the Cockcroft-Gault formula.
- Clinically significant impaired hepatic function defined as an ALT (alanine transaminase) level > 5 times the normal upper limit.
- Subjects with active liver disease.
- Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations.
- Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir or valganciclovir.
- Subjects with malabsorption or vomiting syndrome or other gastrointestinal dysfunction that might impair drug pharmacokinetics.
- Women contemplating pregnancy within the duration of the study drug dosing period.
- Women who are pregnant and/or nursing mothers
- Current history of alcohol or drug abuse.
- Received suppressive (daily) therapy for genital herpes prior to enrollment.
Where it is running
- GSK Investigational Site — Phoenix, Arizona, United States
- GSK Investigational Site — Tucson, Arizona, United States
- GSK Investigational Site — Anaheim, California, United States
- GSK Investigational Site — Beverly Hills, California, United States
- GSK Investigational Site — Davis, California, United States
- GSK Investigational Site — Fair Oaks, California, United States
- GSK Investigational Site — Los Angeles, California, United States
- GSK Investigational Site — Sacramento, California, United States
- GSK Investigational Site — Sacramento, California, United States
- GSK Investigational Site — San Diego, California, United States
- GSK Investigational Site — San Diego, California, United States
- GSK Investigational Site — San Francisco, California, United States
- GSK Investigational Site — Santa Ana, California, United States
- GSK Investigational Site — Hartford, Connecticut, United States
- GSK Investigational Site — New Britain, Connecticut, United States
- GSK Investigational Site — Clearwater, Florida, United States
- GSK Investigational Site — Coral Gables, Florida, United States
- GSK Investigational Site — Melbourne, Florida, United States
- GSK Investigational Site — Palm Springs, Florida, United States
- GSK Investigational Site — Venice, Florida, United States
- GSK Investigational Site — West Palm Beach, Florida, United States
- GSK Investigational Site — Alpharetta, Georgia, United States
- GSK Investigational Site — Atlanta, Georgia, United States
- GSK Investigational Site — Atlanta, Georgia, United States
- GSK Investigational Site — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.